Navigation Links
Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical

Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical -- JENA, Germany, October 22, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Legal Issues Click to view news release full screen  

Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical


JENA, Germany, October 22, 2010 /PRNewswire/ -- Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable appeal court ruling from The Hague, The Netherlands in the on-going patent litigation with AGA Medical. A favourable first instance court ruling obtained by Occlutech had been appealed by AGA in 2008.

In the new ruling the appeal court of The Hague saw no reason to change the favourable first instance ruling. The Dutch appeal court decision is similar to the first instance as well as the appeal court rulings in the UK, the last one received in mid 2010. The rulings are subject to further appeal by AGA.

In Germany where Occlutech lost in the district and appeal courts of Dusseldorf in 2007 and 2008, causing a halt of sales and manufacturing activities in Germany, the German Supreme Court, (BGH), recently announced that it has allowed Occlutech's appeal. Occlutech expects a final decision in the first half of 2011 that, if in Occlutech's favour, will trigger substantial claims for re-payments and damages. Due to the litigation activity by AGA from 2006 and onwards, Occlutech has lost revenue, had products being destroyed and suffered the cost of litigation leading to potential damage claims in excess EUR 50 million.

In spite of the significant cost caused by the litigation and the related lack of sales in several markets, Occlutech's owners have funded work in maintaining and substantially strengthening Occlutech's own patent position and on a full pipe line of new technologies and products. In 2011 and 2012 Occlutech expects to launch additional occluders for indications such as PDA and VSD in addition to second generation ASD and PFO occluders. In addition, an innovative LAA occluder, a new generation of stent grafts and cardiac valve intervention technology are being developed.

SOURCE Occlutech GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Dutch Cancer Center Commences Treatments Using New TrueBeam from Varian Medical Systems
2. Dutch Public-Private Partnership Invests 28 Million Euro on Research Into Personalized Medicine
3. Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
4. Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer
5. Maxygen, Inc. Commences Dutch Auction Tender Offer to Repurchase 6,557,377 Shares of Common Stock
6. Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note
7. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
8. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
11. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
Post Your Comments:
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new ... systems. The new app features a more intuitive SleepScore™ that rates sleep quality on ... slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):